Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

109.62 -2.18 (-1.95%)
Streaming Delayed Price Updated: 3:25 PM EDT, Sep 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
1 Growth Stock Set to Flourishand 2 We Brush Off
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
Topics Supply Chain
News headline image
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Lookin... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Mid-Cap Stock for Long-Term Investors and 2 That Underwhelm
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
Corcept Therapeutics (NASDAQ:CORT) Surges 21% After Q2 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup ↗
Via Chartmill
News headline image
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Surging Stock to Own for Decades and 2 We Brush Off
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne... 
Via StockStory
News headline image
3 Cash-Producing Stocks We Steer Clear Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
Corcept Therapeutics Q2 Earnings Call Highlights ↗
Corcept Therapeutics (NASDAQ:CORT) reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing’s syndrome franchise increased and its newly... 
Via MarketBeat
Topics Earnings
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4%
Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.7% year on year t... 
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept (CORT) Q2 Earnings: What To Expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect. Corcept mi... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Corcept (CORT) Stock Is Down Today
What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to '... 
Via StockStory
News headline image
Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1
Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season. Lo... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know ↗
Atabak exercised options and immediately liquidated shares under a pre-established Rule 10b5-1 trading plan adopted in December 2025. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound ↗
This sale was executed under a Rule 10b5-1 trading plan adopted in March, while the stock has gained 25% over the past year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook ↗
William Guyer's pre-scheduled disposition under a Rule 10b5-1 plan liquidates some direct holdings while retaining 130,000 derivative securities. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Cash-Heavy Stocks with Questionable Fundamentals
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
3 High-Flying Stocks We Steer Clear Of
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta... 
Via StockStory
News headline image
3 Unpopular Stocks We Steer Clear Of
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 Reasons to Sell CORT and 1 Stock to Buy Instead
Corcept’s stock price has taken a beating over the past six months, shedding 35% of its value and falling to $50.98 per share. This was partly driven by its ... 
Via StockStory
News headline image
3 High-Flying Stocks We Think Twice About
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.